Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Praxis Precision Medicines, Inc. - Common Stock (NQ: PRAX )

38.34 -0.23 (-0.60%)
Streaming Delayed Price Updated: 9:31 AM EDT, Mar 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 5,829
Open 38.47
Bid (Size) 37.68 (5)
Ask (Size) 39.00 (4)
Prev. Close 38.57
Today's Range 38.20 - 38.47
52wk Range 30.01 - 91.83
Shares Outstanding 44,712,538
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Praxis Precision Medicines to Participate in Five Upcoming Investor Conferences
From Praxis Precision Medicines, Inc.
Via GlobeNewswire

Performance

YTD
-51.79%
-51.79%
1 Month
-54.81%
-54.81%
3 Month
-48.97%
-48.97%
6 Month
-33.83%
-33.83%
1 Year
-29.68%
-29.68%

More News

Read More
Analysts Cut Price Targets For Praxis Precision After Trial Setback For Essential Tremor Candidate
Via Benzinga
Assessing Praxis Precision Medicine: Insights From 5 Financial Analysts
Via Benzinga
The Analyst Verdict: Praxis Precision Medicine In The Eyes Of 4 Experts
Via Benzinga
Expert Outlook: Praxis Precision Medicine Through The Eyes Of 5 Analysts
Via Benzinga
Keep an eye on the top gainers and losers in Friday's session.
Via Chartmill
Friday's session: top gainers and losers
Via Chartmill
These stocks are gapping in today's session
Via Chartmill
Expert Ratings For Praxis Precision Medicine
Via Benzinga
Praxis Precision Medicines Provides Update on Essential3 and Corporate Update
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Praxis Precision Medicines to Present at Two February Investor Conferences
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Praxis Precision Medicines Highlights 2025 Corporate Strategy and Business Priorities
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Praxis Precision Medicines to Present at J.P. Morgan Healthcare Conference
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Praxis Precision Medicines Announces Rare Pediatric Disease Designation Granted for Relutrigine in Dravet Syndrome
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
9 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Praxis Precision Medicines to Present at Upcoming December Investor Conferences
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Praxis Precision Medicines to Showcase Updates from Largest Epilepsy Pipeline of Precision Epilepsy Programs at the 2024 American Epilepsy Society Annual Meeting
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Praxis Precision Medicines to Participate in Three Upcoming November Investor Conferences
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2024 Financial Results
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Praxis Precision Medicines to Announce Third Quarter 2024 Financial Results and Host Conference Call on Wednesday, November 6, 2024
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Praxis Precision Medicines presents on ulixacaltamide Essential3 program at the Movement Disorders Society 2024 International Congress
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Praxis Precision Medicines to Participate in Upcoming Investor Conferences
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.